^(131)I治疗前后Graves病患者CXCL10、CCL22水平表达变化的研究  

Changes of CXCL10 and CCL22 in patients with Graves' disease after radioactive iodine therapy

作　　者：谭淑君[1] 李春北[2] 李铭[3] 

机构地区：[1]攀枝花市第二人民医院内分泌科,四川攀枝花617068 [2]攀枝花市中心医院内分泌科,四川攀枝花617067 [3]卫生部北京医院内分泌科实验室,北京100730

出　　处：《海南医学》2014年第14期2102-2104,共3页Hainan Medical Journal

摘　　要：目的观察131I治疗前后Graves病患者CXCL10和CCL22水平表达的变化,为Graves病的临床治疗提供新的思路。方法收集内分泌科2012年6月至2013年6月收治的Graves病患者46例(Graves病组),另取同期我院体检中心检查的健康者40例作为对照(对照组)。CXCL10和CCL22表达的测定使用ELISA法,Th1和Th2细胞比例使用流式细胞仪检测。结果对照组CXCL10和CCL22的表达水平分别为(16.8±6.3)ng/L和(150.4±22.6)ng/L,显著低于Graves病组治疗前的(62.4±13.2)ng/L和(161.3±25.4)ng/L(P<0.05,P<0.01),131I治疗后CXCL10和CCL22的表达水平均显著减低(P<0.05,P<0.01),但CXCL10仍高于对照组(P<0.05),而CCL22与对照组之间差异无统计学意义(P>0.05)。两组之间CXCL10/CCL22比值差异也有统计学意义(P<0.05)。正常对照组Th1和Th2细胞比例分别为(1.04±0.41)%和(2.28±0.67)%,显著低于Graves病组治疗前的(8.16±1.62)%和(2.82±0.73)%(P<0.05,P<0.01),131I治疗后Th1和Th2细胞比例均出现了显著的减低(P<0.05,P<0.01),但Th1细胞仍高于对照组(P<0.05),而Th2细胞与对照组之间差异无统计学意义(P>0.05)。两组之间Th1/Th2比值差异也有统计学意义(P<0.05)。结论 Graves病患者中存在CXCL10和CCL22表达水平的升高,131I治疗后可降低CXCL10和CCL22表达水平,调节Th1/Th2细胞的失衡,CXCL10和CCL22因子的检测有可能作为131I治疗反应性的一个指标。Objective To detect the changes of CXCL10 and CCL22 in patients with Graves＇ disease （GD） after radioactive iodine therapy. Methods Forty-six patients with GD were enrolled into our study （GD group）. An-other 40 healthy people were used as normal controls （control group）. CXCL10 and CCL22 were detected by ELIAS. Th1 and Th2 cells was detected by flow cytometry. Results The expression levels of CXCL10 and CCL22 was （16.8±6.3） ng/L and （150.4±22.6） ng/L in control group, （62.4±13.2） ng/L and （161.3±25.4） ng/L in GD group （P〈0.05, P〈0.01）. After 131I therapy, the expression levels of CXCL10 and CCL22 was significantly reduced （P〈0.05, P〈0.01）, but CXCL10 was still higher than that in control group （P〈0.05）. There were also significant differences of CXCL10/CCL22 ratio between the two groups （P〈0.05）. The ratio of Th1 and Th2 cells were （1.04 ± 0.41）% and （2.28 ± 0.67）% in control group, which was significantly lower than （8.16 ± 1.62）% and （2.82 ± 0.73）% in GD group （P〈0.05, P〈0.01）. After 131I therapy, the ratio of Th1 and Th2 cells were significantly reduced （P〈0.05, P〈0.01）, but the ratio of Th1 cells were still higher than that in control group （P〈0.05）. There were also significant differences of Th1/Th2 ratio between the two groups （P〈0.05）. Conclusion Increased expression of CXCL10 and CCL22 is found in Graves＇ disease. 131I therapy can reduce the expression levels of CXCL10 and CCL22, which regulates the imbal-ance of Th1/Th2. Detection of CXCL10 and CCL22 may be used as the indicator of response to 131I treatment.

关 键 词：GRAVES病 CXCL10 CCL22 131I治疗 

分 类 号：R593[医药卫生—内科学]